CRP and myocardial infarction: Researchers have shown that the intake of canakinumab, a monoclonal antibody directed against IL-1, that is used in clinical practice for treatment of some rheumatological diseases, significantly reduced the risk of recurrence of cardiovascular events in patients with history of myocardial infarction and persistently high CRP levels, confirming the close link between inflammation and atherosclerosis [14].